5 Top Gainers In Healthcare Sector (IMUX, KRYS, NERV...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Immunic Inc. (IMUX)

Immunic is a clinical-stage biopharmaceutical company developing oral immunology therapies for chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis.

Gained 90.86% to close Monday's (June 24) trading at $17.75.

News: The previously unpublished data regarding the Company's lead program, IMU-838, were presented at the GI Inflammatory Diseases Summit (GIIDS) in Boston.

The newly released findings were related to preclinical data of IMU-838.

Clinical Trials & Near-term Catalysts:

-- A phase II study of IMU-838 for ulcerative colitis, dubbed CALDOSE-1, is underway, with top-line data expected to be available in the first quarter of 2021. -- A phase II study of IMU-838 for relapsing-remitting multiple sclerosis, dubbed EMPhASIS, is ongoing, with topline data anticipated to be available during the third quarter of 2020. -- A phase II study of IMU-838 in Crohn's disease, dubbed CALDOSE-2, is expected to begin during the second half of 2019. -- A phase I trial of IMU-935 in healthy volunteers and psoriasis patients is expected to begin during September 2019. -- A phase I trial of IMU-856 is expected to begin in H1 2020. IMU-856 targets inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

2. Krystal Biotech Inc. (KRYS)

Krystal Biotech is a gene therapy company focused on developing novel treatments for patients suffering from dermatological diseases through its proprietary gene therapy platform, known as Skin TARgeted Delivery platform, or STAR-D platform.

The Company's lead product candidate is KB103, a first-in-class topical gene therapy, for the treatment of dystrophic epidermolysis bullosa, or DEB, under phase I/II trial.

Gained 41.34% to close Monday's trading at $41.20.

News: The Company announced positive results from its phase II clinical trial of KB103 (GEM-2) study and an update on results from Phase 1 (GEM-1) study in patients with dystrophic epidermolysis bullosa.

According to the Company, five out of six wounds treated with KB103 in the phase II trial closed 100% during the trial. The average time to complete 100% wound closure on KB103 treated wounds in the phase II trial was 23 days.

The Company anticipates commencing the phase III pivotal trial of KB103 before year end 2019.

3. Minerva Neurosciences Inc. (NERV)

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders.

Gained 40.19% to close Monday's trading at $5.93.

News: The Company announced positive results from its phase IIb trial of Seltorexant in insomnia.

The trial demonstrated highly statistically significant and clinically meaningful improvement on Latency to Persistent Sleep (LPS) at Night 1, the primary endpoint of the study.

The key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO-6) at Night 1, showed significant improvement after treatment with 10 and 20 mg doses of Seltorexant.

4. VBI Vaccines Inc. (VBIV)

VBI Vaccines is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines.

The Company's marketed product is Sci-B-Vac, a hepatitis B vaccine that is approved for use in Israel and 10 other countries.

Sci-B-Vac is under a pivotal phase III clinical program, dubbed PROTECT and CONSTANT, in the U.S.

The Company announced positive top-line results from PROTECT study on June 17, 2019. The PROTECT study evaluated the efficacy and safety of a 10 µg dose of Sci-B-Vac with a 20 µg dose of the comparator vaccine, GlaxoSmithKline's Engerix-B.

Near-term Catalyst:

The top-line results from the second pivotal Phase 3 study, CONSTANT, are expected around year-end 2019.

5. Melinta Therapeutics Inc. (MLNT)

Gained 17.10% to close Monday's trading at $5.89.

News: No news

Near-term Catalyst:

The FDA decision on the Company's supplemental New Drug Application for BAXDELA, seeking to include adult patients with community-acquired bacterial pneumonia, for priority review is expected on October 24, 2019.

BAXDELA was approved by the FDA in 2017 for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.